Transposon Therapeutics receives ARPA-H award for TPN-101
The up to $22M funding supports studying TPN-101 to extend healthspan under the PROSPR program. It targets LINE-1 inhibition to slow aging-related diseases.
Latest Transposon Therapeutics News & Updates
See the latest news and media coverage for Transposon Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company developing therapies for neurodegenerative and aging-related diseases
transposonrx.com- Headquarters
- San Diego, United States
- Founded year
- 2020
- Company type
- Private company
- Number of employees
- 11–50
- Industry
- Pharmaceuticals
Last updated
Latest news about Transposon Therapeutics
In short: Transposon Therapeutics advanced TPN-101 through FDA Fast Track, ARPA-H funding, ADDF investment, and ALS platform inclusion.
Company announcements
Transposon receives ADDF investment for TPN-101 Alzheimer’s trial
Plans Phase 2 trial in Q4 2025, building on positive PSP and ALS results. Advances in HEALEY ALS trial.
Transposon Therapeutics announces TPN-101 inclusion
TPN-101 joins Phase 2/3 HEALEY ALS Platform Trial after promising Phase 2 results in C9orf72-related ALS.
Transposon announces Phase 2 results for TPN-101
TPN-101 reduced Vital Capacity decline by 50%, slowed ALS progression, lowered biomarkers. Plans Phase 3 for C9orf72-related ALS.
Media coverage
Transposon Therapeutics’ TPN-101 for Progressive Supranuclear Palsy Gets Fast Tracked | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
The FDA granted fast track designation to TPN-101, an investigational therapy for progressive supranuclear palsy, based on promising phase 2a study results.
Transposon Therapeutics’ TPN-101 to be Studied for Extending Healthy Aging under ARPA-H Award for up to $22M - BioSpace
SAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) -- Transposon Therapeutics, a biotechnology company developing therapies for the treatment of neurodegenerative and aging-related diseases, today announced...
Transposon Receives Investment From The Alzheimer's Drug Discovery Foundation To Support Advancement Of TPN-101 For The Treatment Of Alzheimer's Disease
Building on the positive results of Phase 2 clinical trials in PSP and ALS, Transposon plans to initiate a Phase 2 clinical trial of TPN-101...
Transposon Announces TPN-101 Selected for Inclusion in the Phase 2/3 HEALEY ALS Platform Trial, Building on the Success of Phase 2 Study in C9orf72-related ALS
News provided by Transposon Therapeutics May 28, 2025, 8:00 AM ET In the Phase 2 Study of TPN-101 in patients with C9orf72-related ALS, TPN-101 showed...
Never miss news about Transposon Therapeutics
Track Transposon Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Transposon Therapeutics competitors & trending companies
Browse news for competitors to Transposon Therapeutics and other trending companies.
Annexon Biosciences
Spinogenix
Acelot
NRG Therapeutics
Harness Therapeutics
Aquilus
Canurta
Dunad
Aperture Therapeutics
Sironax
uniQure
SharkNinja
NRx
Ropes & Gray
HighTech Kaunas
inretrn
Poundland
Farrer & Co
Specialfastigheter
SISAB
Hemsö
Stenvalvet
Liljewall
Veidekke
Locum
NCC
Kriminalvården
Archus
Nyréns
Peab
MVB
VGR fastigheter
AIX
ByggDialog
Tengbom
LINK